Abstract
Cancer is the most lethal ailment throughout the world in the present era. The development of new anticancer remedies with minor unhealthful effects and an alternate mechanism is crucial. Benzimidazole is a distinguished heterocyclic compound and is now recognized as the privileged scaffold for new drug discovery. This chapter deals with the anticancer capability of benzimidazolium salts and their metal complexes. The benzimidazolium derivatives have been prepared by the introduction of aliphatic and aromatic groups at two nitrogen atoms of the benzimidazole ring. Other modifications include hybridization with other pharmacophores and the preparation of metal complexes. The potent derivatives presented in this review can serve as novel drug candidates against cancer.
Keywords
- benzimidazolium salts
- Benzimidazole
- metal complexes
- salts
- hybrid
- silver
- breast cancer (MCF-7) cell line
- colon cancer (HCT-116) cell line
1. Introduction
Cancer is among the most dreadful diseases and a significant cause of assassinations all over the globe. In 2018, 9.6 million expirations were because of this malady [1]. Breast cancer is the paramount form of cancer in women all over the world. In 2018, 2.3 million victims and 627,000 fatalities were reported due to breast cancer. Prostate cancer is the second most common cancer in males and 1.3 million patients were reported in 2018 [1]. It has been deduced that more than 13 million people will die due to cancer in 2030 [2]. The major risk factors associated with cancer are chronic infections, inherited mutations in genes, overweight, no physical activity, exposure to ionizing radiation, and carcinogens such as polychlorinated biphenyls, chloroform, Dichlorodiphenyltrichloroethane (DDT), and formaldehyde [3]. Treatment patterns for cancer involve radiotherapy, surgery, and drug therapy. Drug therapy includes inorganic, organic, organometallic monomers, and polymers as well as nanoparticles [4]. Drug therapy is associated with severe adverse properties such as alopecia, anemia, and infertility. There is also the development of resistance against currently available drugs [5]. Consequently, the development of new anticancer drugs affiliated with low toxicities is very significant.
Nitrogen-containing heterocycles are abundantly present in natural and synthetic drug molecules [6]. Benzimidazole is one of the most significant members of nitrogen-containing heterocycles. This heterocycle is a constituent of the structures of some natural compounds such as vitamin B12 [7]. Benzimidazole derivatives have antihypertensive [8], anti-inflammatory [9], antimicrobial [10], antiulcer [11], antiviral [12], antioxidant [13], antitumor [14], lipid modulator, and anticoagulant properties [15]. Benzimidazole derivatives have also the major therapeutic activities against cancer [16, 17, 18]. Benzimidazole is also the main pharmacophore of anticancer drugs (Figure 1) such as bendamustine (
2. Anticancer properties of benzimidazolium salts
Benzimidazolium salts and their anticancer capabilities have been reviewed in the following sections.
2.1 Hybrid molecules containing benzimidazolium salts
Molecular hybridization has become an effective approach for new drug discovery. In molecular hybridization, two or more pharmacophores are linked to each other to produce the new molecules [24, 25]. Yang et al. synthesized hybrid molecules in which benzimidazolium salts were linked to trimethoxy phenyl chalcones. Compound
Xu et al. coupled a three-substituted indole ring with imidazolium salts to produce new hybrid molecules. Upon evaluation of anticancer activity, compound
2.2 Benzimidazolium salts having aromatic and aliphatic substituents
Akkoc et al. reported benzimidazolium salts screened for anticancer potential against human embryonic kidney (HEK-293 T), human colon epithelial colorectal adenocarcinoma (DLD-1), and human breast epithelial adenocarcinoma (MDA-MB-231) cancer cell lines by using MTT assay. Palladium (Pd) metal complexes were also prepared and found inactive against these cells lines having IC50 values over 100 μM. The naphthalen-1-yl-methyl incorporated benzimidazolium chloride
Lin et al. synthesized 1,3-bis-naphthyl-substituted benzimidazolium bromides and estimated for activity against MDA-MB-468 as well as PC-3 cell lines. As compared to the standard drug tamoxifen (IC50 = 22.5 μM), compound
Bansode et al. carried out the synthesis of ferrocene-linked ionic liquids by incorporating long alkyl chains. Anticancer activity was evaluated against MCF-7 by using sulforhodamine B assay. These ferrocene-quaternized azolium salts showed significant cytotoxic potential against MCF-7 and 1-(ferrocenylmethyl)-3-tetradecylbenzimidazolium bromide
2.3 Benzimidazolium silver metal complexes
Cisplatin is the first metal-based drug used for the cure of cancer [49]. The serendipitous discovery of cisplatin stimulated the search for new metal-based anticancer agents. Silver (Ag) salts have been used as antimicrobial agents for purification of drinking water and wound healing [50, 51]. Based on its antimicrobial property, silver has also been explored as an anticancer agent.
2.3.1 Bis-benzimidazolium silver metal complexes
Iqbal and his coworkers performed a detailed study to reduce the risk of malignant neoplasm and reported novel binuclear benzimidazolium salt and corresponding Ag (I) NHC complex. Compound
Achar et al. reported a novel series based on benzimidazolium salts linked with coumarin heterocycle, and their silver cationic bis-NHC and Ag neutral mono-NHC were synthesized. The anticancer activity was evaluated by sulforhodamine assay. Complex
Similarly, Haque et al. prepared Ag(I) complexes containing nitrile-functionalized benzimidazolium salt as an active agent against HCT-116. Among all synthesized complexes, compound
2.3.2 Benzimidazolium silver and gold metal complexes
Akkoc et al. reported a series of silver- and palladium-based metal complexes with benzimidazolium ligand. This attempt was made in search of the non-platinum antitumor drugs due to the observed side effects of cisplatin and nedaplatin. However, silver complex
Similarly, the synthetic work of Cevik Yildiz and his coworkers resulted in the formation of novel benzimidazolium salt. These benzimidazolium salts were used as a ligand to obtain corresponding novel Ag (I)- benzimidazolium complexes. Cytotoxic studies of salts and complexes were carried out against MCF-7, MDA-MB-23, DU-145 by MTT assay. Compound
2.4 Selenium-based benzimidazolium salts and complexes
Selenium (Se) is very important for the human body and its deficiency can lead to cancer, diabetes, and cardiovascular diseases [73]. Selenium is present in some food and drinks in traces [74]. Recently, selenium has been incorporated in new anticancer agents due to its low toxicity. Kamal et al. applied a green synthetic approach to obtain novel benzimidazolium salts and Se-based benzimidazolium-heterocyclic carbenes. The
2.5 Ruthenium complexes based on benzimidazolium salts
Organic compounds having ruthenium (Ru) metal are also being used as anticancer agents. Akkoc et al. synthesized methylpyridine-linked benzimidazolium salt and corresponding Ru (II) complexes containing benzimidazolium ligand. The antiproliferative assay revealed that
2.6 Miscellaneous metal complexes
As mentioned earlier, NHC-carbenes are highly reactive species depending upon the nature of the ligand and transition metal used; consequently, different transition metals have been coordinated with benzimidazolium ligand for a better cytotoxic effect. Troung et al. studied the cytotoxicity of rhodium (Rh)- and iridium (Ir)-based benzimidazolium complexes. A series of rhodium and iridium complexes were prepared and evaluated for anticancer potential against HCT-116, NCI-H460, SiHa, SW480 human cancer cell lines. Compounds
3. Conclusion
The pharmacological properties of benzimidazolium salts have attracted the attention of medicinal chemists. The resemblance of benzimidazole scaffold with purine bases establishes it biologically significant. Benzimidazolium salts have demonstrated promising activities against various cancer cell lines. Benzimidazolium salts derivatives have been prepared by the functionalization of two nitrogen atoms in the imidazole ring along with the preparation of hybrid molecules, and metal complexes. The hybridization of benzimidazole salts with natural compounds such as chalcones and steroids exhibited prominent activities (IC50 < 1 μM) against various cancer cell lines. Some hybrids compounds also showed the phenomenon of apoptosis. Compounds carrying alkyl chains and aromatic rings at benzimidazole nitrogen showed pronounced activity. The introduction of phenyl, naphthalene, anthracene, and quinoline rings at the benzimidazole nitrogens through methylene groups intensified the anticancer activity. The 5,6-dimethyl-substituted benzimidazole derivatives were also found more active as compared to unsubstituted benzimidazole rings. In the case of silver metal complexes, bis-benzimidazolium complexes exhibited exceptional activity against colon cancer (IC50 < 1 μM) cell line. But silver metal complexes presented less selectivity indices. Mono-benzimidazolium metal complexes proved more active against breast cancer (IC50 < 1 μM) cell lines. In some derivatives, the introduction of a long alkyl chain at the benzimidazole nitrogen is beneficial for the augmentation of anticancer activity. The activity of selenium metal complexes was almost equivalent to their respective salts. While the halogen-substituted ruthenium benzimidazole metal complexes showed moderate activity. Rhodium, platinum, and gold complexes have also shown encouraging anticancer activities and are excellent candidates for future investigations. The
References
- 1.
Bray F, Ferlay J, Soerjomataram I. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018; 68 (6):394-424. DOI: 10.3322/caac.21492 - 2.
Bray F, Jemal A, Grey N. Global cancer transitions according to the Human Development Index (2008-2030): A population-based study. The Lancet Oncology. 2012; 13 (8):790-801. DOI: 10.1016/S1470-2045(12)70211-5 - 3.
Danaei G, Vander Hoorn S, Lopez AD, Comparative Risk Assessment collaborating group (Cancers). Causes of cancer in the world: Comparative risk assessment of nine behavioural and environmental risk factors. The Lancet. 2005; 366 (9499):1784-1793. DOI: 10.1016/S0140-6736(05)67725-2 - 4.
Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: Current perspectives and new challenges. Ecancermedicalscience. 2019; 13 :961. DOI: 10.3332/ecancer.2019.961 - 5.
Masoud V, Pages G. Targeted therapies in breast cancer: New challenges to fight against resistance. World Journal of Clinical Oncology. 2017; 8 (2):120-134. DOI: 10.5306%2Fwjco.v8.i2.120 - 6.
Vitaku E, Smith DT, Njardarson JT. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among us FDA approved pharmaceuticals. Journal of Medicinal Chemistry. 2014; 57 (24):10257-10274. DOI: 10.1021/jm501100b - 7.
Barker HA, Smyth RD, Weissbach H. Isolation and properties of crystalline cobamide coenzymes containing benzimidazole or 5, 6-dimethy lbenzimidazole. Journal of Biological Chemistry. 1960; 235 (2):480-488. DOI: 10.1016/s0021-9258(18)69550-x - 8.
Khan MT, Razi MT, Jan SU. Synthesis, characterization, and antihypertensive activity of 2-phenyl substituted benzimidazoles. Pakistan Journal of Pharmaceutical Sciences. 2018; 31 (3):1067-1074. DOI: 10.36721/pjps.2019.32.6.reg.2585-2597.1 - 9.
Kaur G, Silakari O. Benzimidazole scaffold-based hybrid molecules for various inflammatory targets: Synthesis and evaluation. Bioorganic Chemistry. 2018; 80 :24-35. DOI: 10.1016/j.bioorg.2018.05.014 - 10.
Al-Blewi FF, Almehmadi MA, Aouad MR. Design, synthesis, ADME prediction, and pharmacological evaluation of novel benzimidazole-1, 2, 3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents. Chemistry Central Journal. 2018; 12 (1):1-14. DOI: 10.1186/s13065-018-0479-1 - 11.
Scheinfeld N. Cimetidine: A review of the recent developments and reports in cutaneous medicine. Dermatology Online Journal. 2003; 9 (2):4. DOI: 10.5070/D33s15q645 - 12.
Vausselin T, Seron K, Lavie M. Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus. Journal of Virology. 2016; 90 (19):8422-8434. DOI: 10.1128/JVI.00404-16 - 13.
Ozil M, Parlak C, Baltas N. A simple and efficient synthesis of benzimidazoles containing piperazine or morpholine skeleton at C-6 position as glucosidase inhibitors with antioxidant activity. Bioorganic Chemistry. 2018; 76 :468-477. DOI: 10.1016/j.bioorg.2017.12.019 - 14.
Hussain A, Alajmi MF, Rehman M. Evaluation of transition metal complexes of the benzimidazole-derived scaffold as promising anticancer chemotherapeutics. Molecules. 2018; 23 (5):1232-1250. DOI: 10.3390/molecules23051232 - 15.
Bharadwaj SS, Poojary B, Nandish SKM. Efficient synthesis and in silico studies of the benzimidazole hybrid scaffold with the quinolinyloxadiazole skeleton with potential α-glucosidase inhibitory, anticoagulant, and antiplatelet activities for type-II diabetes mellitus management and treating thrombotic disorders. ACS Omega. 2018; 3 (10):12562-12574. DOI: 10.1021/acsomega.8b01476 - 16.
Wang YT, Shi TQ, Zhu HL. Synthesis, biological evaluation, and molecular docking of benzimidazole grafted benzsulfamide-containing pyrazole ring derivatives as novel tubulin polymerization inhibitors. Bioorganic & Medicinal Chemistry. 2019; 27 (3):502-515. DOI: 10.1016/j.bmc.2018.12.031 - 17.
Ibrahim HS, Albakri ME, Mahmoud WR. Synthesis and biological evaluation of some novel thiobenzimidazole derivatives as anti-renal cancer agents through inhibition of c-MET kinase. Bioorganic Chemistry. 2019; 85 :337-348. DOI: 10.1016/j.bioorg.2019.01.006 - 18.
Min R, Wu W, Wang M. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo-propyl) pyrrolidine-3-yl)-1 H -benzo [d] imidazole-4-carboxamide: A potent poly (ADP-ribose) polymerase (PARP) inhibitor for treatment of cancer. Molecules. 2019;24 (10):1901. DOI: 10.3390/molecules24101901 - 19.
Gaba M, Mohan C. Development of drugs based on imidazole and benzimidazole bioactive heterocycles: Recent advances and future directions. Medicinal Chemistry Research. 2016; 25 (2):173-210. DOI: 10.1007/s00044-015-1495-5 - 20.
Purushottamachar P, Ramalingam S, Najar VC. Development of benzimidazole compounds for cancer therapy. In: Chemistry and Applications of Benzimidazole and its Derivatives. 2019. pp. 1-15. DOI: 10.5772/ intechopen.86691 - 21.
Narasimhan B, Sharma D, Kumar P. Benzimidazole: A medicinally important heterocyclic moiety. Medicinal Chemistry Research. 2012; 21 (3):269-283. DOI: 10.1007/s00044-010-9533-9 - 22.
Gupta S, Basu B, Das S. Benzimidazole-based palladium- N -heterocyclic carbene: A useful catalyst for C-C cross-coupling reaction at ambient condition. Tetrahedron. 2013;69 (1):122-128. DOI: 10.1016/j.tet.2012.10.055 - 23.
Medici S, Peana M, Crisponi G. Silver coordination compounds: A new horizon in medicine. Coordination Chemistry Reviews. 2016; 327 :349-359. DOI: 10.1016/j.ccr.2016.05.015 - 24.
Viegas-Junior C, Danuello A, da Silva Bolzani VDS. Molecular hybridization: A useful tool in the design of new drug prototypes. Current Medicinal Chemistry. 2007; 14 (17):1829-1852. DOI: 10.2174/092986707781058805 - 25.
Singh A, Singh JV, Rana A. Monocarbonyl curcumin-based molecular hybrids as potent antibacterial agents. ACS Omega. 2019; 4 (7):11673-11684. DOI: 10.1021/acsomega.9b01109 - 26.
Yang JL, Ma YH, Li YH. Design, synthesis, and anticancer activity of novel trimethoxyphenyl-derived chalcone-benzimidazolium salts. ACS Omega. 2019; 4 (23):20381-20393. DOI: 10.1021/acsomega.9b03077 - 27.
Karatas MO, Tekin S, Alici B. Cytotoxic effects of coumarin substituted benzimidazolium salts against human prostate and ovarian cancer cells. Journal of Chemical Sciences. 2019; 69 :131. DOI: 10.1007/s12039-019-1647-0 - 28.
Wang XQ, Chen XB, Ye PT. Synthesis and biological evaluation of novel 3-benzylcoumarin-imidazolium salts. Bioorganic & Medicinal Chemistry Letters. 2020; 30 (4):126896. DOI: 10.1016/j.bmcl.2019.126896 - 29.
Deng G, Zhou B, Wang J. Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives. European Journal of Medicinal Chemistry. 2019; 168 :232-252. DOI: 10.1016/j.ejmech.2019.02.025 - 30.
Nirmal NP, Rajput MS, Prasad RGSV. Brazilin from Caesalpinia sappan heartwood and its pharmacological activities: A review. Asian Pacific Journal of Tropical Medicine. 2015;8 (6):421-430. DOI: 10.1016/j.apjtm.2015.05.014 - 31.
Huang M, Duan S, Ma X. Synthesis and antitumor activity of aza-brazilan derivatives containing imidazolium salt pharmacophores. MedChemComm. 2019; 10 (6):1027-1036. DOI: 10.1039/C9MD00112C - 32.
Zhou B, Liu ZF, Deng GG. Synthesis and antitumor activity of novel N -substituted tetrahydro-beta-carboline-imidazolium salt derivatives. Organic & Biomolecular Chemistry. 2016;14 (39):9423-9430. DOI: 10.1039/C6OB01495J - 33.
Xu XL, Wang J, Yu CL. Synthesis and cytotoxic activity of novel 1-((indol-3-yl)methyl)-1H-imidazolium salts. Bioorganic & Medicinal Chemistry Letters. 2014; 24 (21):4926-4930. DOI: 10.1016/j.bmcl.2014.09.045 - 34.
Li YH, Zhou B, Shi YM. Novel 3-substituted N -methylcarbazole-imidazolium salt derivatives: Synthesis and cytotoxic activity. Chemical Biology & Drug Design. 2018;92 (1):1206-1213. DOI: 10.1111/cbdd.13178 - 35.
Wang XQ, Ye PT, Bai MJ. Synthesis and biological activity of new bisbenzofuran-imidazolium salts. Bioorganic & Medicinal Chemistry Letters. 2020; 30 (13):127210. DOI: 10.1016/j.bmcl.2020.127210 - 36.
Zhang CB, Liu Y, Liu ZF. Synthesis and cytotoxic activity of novel tetrahydrobenzodifuran-imidazolium salt derivatives. Bioorganic & Medicinal Chemistry Letters. 2017; 27 (8):1808-1814. DOI: 10.1016/j.bmcl.2017.02.053 - 37.
Zhou Y, Duan K, Zhu L. Synthesis and cytotoxic activity of novel hexahydropyrrolo[2,3-b]indole imidazolium salts. Bioorganic & Medicinal Chemistry Letters. 2016; 26 (2):460-465. DOI: 10.1016/j.bmcl.2015.11.092 - 38.
Akkoc S, Kayser V, Ilhan IO. New compounds based on a benzimidazole nucleus: Synthesis, characterization and cytotoxic activity against breast and colon cancer cell lines. Journal of Organometallic Chemistry. 2017; 839 :98-107. DOI: 10.1016/j.jorganchem.2017.03.037 - 39.
Akkoc S, Kayser V, Ilhan IO. Synthesis and in vitro anticancer evaluation of some benzimidazolium salts. Journal of Heterocyclic Chemistry. 2019;56 (10):2934-2944. DOI: 10.1002/jhet.3687.svg - 40.
Akkoc S. Antiproliferative activities of 2-hydroxyethyl substituted benzimidazolium salts and their palladium complexes against human cancerous cell lines. Synthetic Communications. 2019; 49 (21):1-12. DOI: 10.1080/00397911.2019.1650187 - 41.
Lin ZJ, Bies J, Johnson SS. Synthesis and anti-proliferative activity of N, N ′-bis-substituted 1,2,4-triazolium salts against breast cancer and prostate cancer cell Lines. Journal of Heterocyclic Chemistry. 2018;56 (2):533-538. DOI: 10.1002/jhet.3428 - 42.
Wright BD, Deblock MC, Wagers PO. Anti-tumor activity of lipophilic imidazolium salts on select NSCLC cell lines. Medicinal Chemistry Research. 2015; 24 :2838-2861. DOI: 10.1007/s00044-015-1330-z - 43.
Stromyer ML, Southerland MR, Satyal U. Synthesis, characterization, and biological activity of a triphenylphosphonium-containing imidazolium salt against select bladder cancer cell lines. European Journal of Medicinal Chemistry. 2020; 185 :111832. DOI: 10.1016/j.ejmech.2019.111832 - 44.
Shelton KL, Debord MA, Wagers PO. Synthesis, anti-proliferative activity, SAR study, and preliminary in vivo toxicity study of substituted N,N' - bis(arylmethyl) benzimidazolium salts against a panel of non-small cell lung cancer cell lines. Bioorganic & Medicinal Chemistry. 2017;25 (1):421-439. DOI: 10.1016/j.bmc.2016.11.009 - 45.
Bansode P, Patil P, Choudhari P. Anticancer activity and molecular docking studies of ferrocene tethered ionic liquids. Journal of Molecular Liquids. 2019; 290 :111182. DOI: 10.1016/j.molliq.2019.111182 - 46.
KucuKbay H, Mumcu A, Tekin S. Synthesis and evaluation of novel N, N' -disubstituted benzimidazolium bromides salts as antitumor agents. Turkish Journal of Chemistry. 2016;40 (3):393-401. DOI: 10.3906/kim-1510-15 - 47.
Haque RA, Iqbal MA, Ahamed MBK. Design, synthesis and structural studies of meta-xylyl linked bis-benzimidazolium salts: Potential anticancer agents against human colon cancer. Chemistry Central Journal. 2012; 6 (1):68. DOI: 10.1186/1752-153x-6-68 - 48.
Huda NU, Islam S, Zia M. Anticancer, antimicrobial and antioxidant potential of sterically tuned bis- N -heterocyclic salts. Zeitschrift für Naturforschung - Section C Journal of Biosciences. 2018;74 (1):17-23. DOI: 10.1515/znc-2018-0095 - 49.
Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205 :698-699. DOI: 10.1038/205698a0 - 50.
Da Silva B, Habibi M, Ognier S. Silver nanocluster catalytic microreactors for water purification. The European Physical Journal Special Topics. 2016; 225 :707-714. DOI: 10.1140/epjst/e2015-50262-6 - 51.
Varaprasad K, Mohan YM, Vimala K. Synthesis and characterization of hydrogel-silver nanoparticle-curcumin composites for wound dressing and antibacterial application. Journal of Applied Polymer Science. 2011; 121 (2):784-796. DOI: 10.1002/app.33508 - 52.
Iqbal MA, Umar MI, Haque RA. Macrophage and colon tumor cells as targets for a binuclear silver(I) N -heterocyclic carbene complex, an anti-inflammatory and apoptosis mediator. Journal of Inorganic Biochemistry. 2015;146 :1-13. DOI: 10.1016/j.jinorgbio.2015.02.001 - 53.
Ghdhayeb MZ, Haque RA, Budagumpi S. Mono- and bis- N -heterocyclic carbene silver(I) and palladium(II) complexes: Synthesis, characterization, crystal structure andin vitro anticancer studies. Polyhedron. 2017;121 :222-230. DOI: 10.1016/j.poly.2016.09.065 - 54.
Sharhan O, Heidelberg T, Hashim NM. Benzimidazolium-acridine-based silver N -heterocyclic carbene complexes as potential anti-bacterial and anti-cancer drug. Inorganica Chimica Acta. 2020;504 :119462. DOI: 10.1016/j.ica.2020.119462 - 55.
Habib A, Nazari VM, Iqbal MA. Unsymmetrically substituted benzimidazolium based Silver(I)- N -heterocyclic carbene complexes: Synthesis, characterization and in vitro anticancer study against human breast cancer and colon cancer. Journal of Saudi Chemical Society. 2019;23 (7):795-808. DOI: 10.1016/j.jscs.2019.03.002 - 56.
Atif M, Bhatti HN, Haque RA. Synthesis, structure and anticancer activity of symmetrical and non-symmetrical silver(I)- N -heterocyclic carbene complexes. Applied Biochemistry and Biotechnology. 2020;191 :1171-1189. DOI: 10.1007/s12010-019-03186-9 - 57.
Achar G, Shahini CR, Patil SA. Sterically modulated silver(I) complexes of coumarin substituted benzimidazol-2-ylidenes: Synthesis, crystal structures and evaluation of their antimicrobial and antilung cancer potentials. Journal of Inorganic Biochemistry. 2018; 183 :43-57. DOI: 10.1016/j.jinorgbio.2018.02.012 - 58.
Yasar S, Koprulu TK, Tekin S. Synthesis, characterisation and cytotoxic properties of N -heterocyclic carbene silver(I) complexes. Inorganica Chimica Acta. 2018;479 :17-23. DOI: 10.1016/j.ica.2018.04.035 - 59.
Karlik O, Balcıoglu S, Karatas MO. Synthesis, structural characterization and cytotoxicity studies of T-shaped silver(I) complexes derived from 1-benzyl-3 H -benzimidazoliump -toluenesulfonates. Polyhedron. 2018;142 :63-70. DOI: 10.1016/j.poly.2017.12.033 - 60.
Fatima T, Haque RA, Razali MR. Effect of lipophilicity of wingtip groups on the anticancer potential of mono N -heterocyclic carbene silver(I) complexes: Synthesis, crystal structures andin vitro anticancer study. Applied Organometallic Chemistry. 2017;31 (10):e3735. DOI: 10.1002/aoc.3735 - 61.
Haque RA, Choo SY, Budagumpi S. Synthesis, crystal structures, characterization and biological studies of nitrile-functionalized silver(I) N -heterocyclic carbene complexes. Inorganica Chimica Acta. 2015;433 :35-44. DOI: 10.1016/j.ica.2015.04.023 - 62.
Haque RA, Choo SY, Budagumpi S. Silver(I) complexes of mono- and bidentate N -heterocyclic carbene ligands: synthesis, crystal structures, andin vitro antibacterial and anticancer studies. European Journal of Medicinal Chemistry. 2015;90 :82-92. DOI: 10.1016/j.ejmech.2014.11.005 - 63.
Hussaini SY, Haque RA, Asekunowo PO. Synthesis, characterization and anti-proliferative activity of propylene linked bis-benzimidazolium salts and their respective dinuclear Silver(I)- N -heterocyclic carbene complexes. Journal of Organometallic Chemistry. 2017;840 :56-62. DOI: 10.1016/j.jorganchem.2017.04.011 - 64.
Hussaini SY, Haque RA, Fatima T. Nitrile functionalized silver(I) N -heterocyclic carbene complexes: DFT calculations and antitumor studies. Transition Metal Chemistry. 2018;43 :301-312. DOI: 10.1007/s11243-018-0216-6 - 65.
Akkoc S, Ozer Ilhan I, Gok Y. In vitro cytotoxic activities of new silver and PEPPSI palladiumN -heterocyclic carbene complexes derived from benzimidazolium salts. Inorganica Chimica Acta. 2016;449 :75-81. DOI: 10.1016/j.ica.2016.05.001 - 66.
Sahin N, Sahin-Bolukbasi S, Tahir MN. Synthesis, characterization and anticancer activity of allyl substituted N -Heterocyclic carbene silver (I) complexes. Journal of Molecular Structure. 2019;1179 :92-99. DOI: 10.1016/j.molstruc.2018.10.094 - 67.
Ozdemir I, Ciftci O, Evren E. Synthesis, characterization and antitumor properties of novel silver(I) and gold(I) N -heterocyclic carbene complexes. Inorganica Chimica Acta. 2020;506 :119530. DOI: 10.1016/j.ica.2020.119530 - 68.
Cevik-Yildiz E, Sahin N, Sahin-Bolukbasi S. Synthesis, characterization, and investigation of antiproliferative activity of novel Ag (I)- N -heterocyclic Carbene (NHC) compounds. Journal of Molecular Structure. 2020;1199 :126987. DOI: 10.1016/j.molstruc.2019.126987 - 69.
Aktas A, Kelestemur U, Gok Y. 2-Morpholinoethyl-substituted N -heterocyclic carbene (NHC) precursors and their silver (I) NHC complexes: Synthesis, crystal structure andin vitro anticancer properties. Journal of the Iranian Chemical Society. 2018;15 :131-139. DOI: 10.1007/s13738-017-1216-8 - 70.
Kızrak U, Ciftci O, Ozdemir I. Amine-fnctionalized silver and gold N -heterocyclic carbene complexes: Synthesis, characterization and antitumor properties. Journal of Organometallic Chemistry. 2019;882 :26-32. DOI: 10.1016/j.jorganchem.2018.12.018 - 71.
Sahin-Bolukbasi S, Sahin N. Novel Silver-NHC complexes: Synthesis and anticancer properties. Journal of Organometallic Chemistry. 2019; 891 :78-84. DOI: 10.1016/j.jorganchem.2019.04.018 - 72.
Sahin-Bolukbasi S, Sahin N, Tahir MN. Novel N -heterocyclic carbene silver(I) complexes: Synthesis, structural characterization, and anticancer activity. Inorganica Chimica Acta. 2019;486 :711-718. DOI: 10.1016/j.ica.2018.11.044 - 73.
Roman M, Jitaru P, Barbante C. Selenium biochemistry and its role for human health. Metallomics. 2014; 6 (1):25-54. DOI: 10.1039/c3mt00185g - 74.
Eiche E, Nothstein AK, Gottlicher J. The behaviour of irrigation induced Se in the groundwater-soil-plant system in Punjab, India. Environmental Science. Processes & Impacts. 2019; 21 (6):957-969. DOI: 10.1039/C9EM00009G - 75.
Kamal A, Nazari M, Yaseen M. Green synthesis of Selenium- N -heterocyclic carbene compounds: Evaluation of antimicrobial and anticancer potential. Bioorganic Chemistry. 2019;90 :103042. DOI: 10.1016/j.bioorg.2019.103042 - 76.
Iqbal MA, Haque RA, Ng WC. Green synthesis of mono- and di-Selenium- N -heterocyclic carbene adducts: Characterizations, crystal structures and pro-apoptotic activities against human colorectal cancer. Journal of Organometallic Chemistry. 2016;801 :130-138. DOI: 10.1016/j.jorganchem.2015.10.023 - 77.
Akkoc M, Balciolu S, Gurses C. Protonated water-soluble N -heterocyclic carbene ruthenium(II) complexes: Synthesis, cytotoxic and DNA binding properties and molecular docking study. Journal of Organometallic Chemistry. 2018;869 :67-74. DOI: 10.1016/j.jorganchem.2018.06.003 - 78.
Onar G, Gurses C, Karatas MO. Palladium (II) and ruthenium (II) complexes of benzotriazole functionalized N -heterocyclic carbenes: Cytotoxicity, antimicrobial, and DNA interaction studies. Journal of Organometallic Chemistry. 2019;886 :48-56. DOI: 10.1016/j.jorganchem.2019.02.013 - 79.
Lam NYS, Truong D, Burmeister H. From catalysis to cancer: Toward structure-activity relationships for benzimidazol-2-ylidene-derived N -heterocyclic-carbene complexes as anticancer Agents. Inorganic Chemistry. 2018;57 (22):14427-14434. DOI: 10.1021/acs.inorgchem.8b02634 - 80.
Truong D, Sullivan MP, Tong KKH. Potent inhibition of thioredoxin reductase by the Rh derivatives of anticancer M(arene/Cp*) (NHC)Cl2 complexes. Inorganic Chemistry. 2020; 59 (3):3281-3289. DOI: 10.1021/acs.inorgchem.9b03640 - 81.
Zhao X, Shi L, He W. Synthesis of novel NHC–Rh complexes with anti-tumor activity against MCF-7 human breast cancer cells. ARKIVOC. 2020; vi :94-104. DOI: 10.24820/ark.5550190.p011.129 - 82.
Sanchez-Mora A, Valdes H, Ramirez-Apan MT. NHC-Ir (I) complexes derived from 5, 6-dinitrobenzimidazole. Synthesis, characterization and preliminary evaluation of their in vitro anticancer activity. Inorganica Chimica Acta. 2019;496 :119061. DOI: 10.1016/j.ica.2019.119061 - 83.
Choo KB, Mah WL, Lee SM. Palladium complexes of bidentate pyridine N -heterocyclic carbenes: Optical resolution, antimicrobial and cytotoxicity studies. Applied Organometallic Chemistry. 2018;32 :e4377. DOI: 10.1002/aoc.4377 - 84.
Sivaram H, Tan J, Huynh HV. Syntheses, characterizations, and a preliminary comparative cytotoxicity study of gold(I) and gold(III) complexes bearing benzimidazole- and pyrazole-derived N -heterocyclic carbenes. Organometallics. 2012;31 (16):5875-5883. DOI: 10.1021/om300444c - 85.
Rehm T, Rothemund M, Bar A. N, N -dialkylbenzimidazol-2-ylidene platinum complexes - effects of alkyl residues and ancillary cis-ligands on anticancer activity. Dalton Transactions. 2018;47 (48):17367-17381. DOI: 10.1039/C8DT03360A